no proven response to PAH-specific medications.
While we agree that SCD-PH is multifactorial, the hemodynamics of precapillary PH in SCD need to be clarified. We have defined precapillary SCD-PH like other PAH subgroups: mean pulmonary arterial pressure 
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We agree that the literature evaluating PAH therapy in SCD-PH is limited. However, we also believe that the 3 clinical trials conducted in these patients are insufficient to determine whether SCD patients with precapillary PH should receive PAH therapy. These trials collectively enrolled only 14 patients with precapillary PH (fewer than half of whom received vasodilators) resulting in imprecisely estimated effects (6,7). There are 4 case series in which SCD patients with precapillary PH were treated with bosentan, sildenafil, and/or epoprostenol. Vasodilator therapy led to an increase in six-minute walk distance 41 to 144 m above baseline (8-10) with improvements in mPAP, PVR, and cardiac index (10) . Based upon these studies combined with our clinical experience, we weakly recommended a trial of either an endothelin receptor antagonist or a prostacyclin analog for select SCD patients with symptomatic precapillary PH.
We are concerned that the 2013 classification will limit access for these patients to clinically beneficial PAH-specific medications.
The reclassification of SCD-PH as Group IV, Group I, and now as Group V reflects the imprecise nature of the classification. It stresses the need to define PH subgroups so that all patients may benefit from the available treatment options. 
